Dimensional Fund Advisors LP trimmed its stake in shares of Stemline Therapeutics, Inc. (NASDAQ:STML) by 13.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,899 shares of the biopharmaceutical company’s stock after selling 10,820 shares during the quarter. Dimensional Fund Advisors LP owned about 0.38% of Stemline Therapeutics worth $589,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Nationwide Fund Advisors raised its holdings in shares of Stemline Therapeutics by 7.8% in the 1st quarter. Nationwide Fund Advisors now owns 11,900 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 858 shares in the last quarter. Wells Fargo & Company MN raised its holdings in shares of Stemline Therapeutics by 3.8% in the 1st quarter. Wells Fargo & Company MN now owns 13,647 shares of the biopharmaceutical company’s stock worth $117,000 after purchasing an additional 500 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Stemline Therapeutics in the 1st quarter worth approximately $120,000. Ameriprise Financial Inc. raised its holdings in shares of Stemline Therapeutics by 8.7% in the 1st quarter. Ameriprise Financial Inc. now owns 43,900 shares of the biopharmaceutical company’s stock worth $375,000 after purchasing an additional 3,500 shares in the last quarter. Finally, Teachers Advisors LLC raised its holdings in shares of Stemline Therapeutics by 30.8% in the 4th quarter. Teachers Advisors LLC now owns 35,195 shares of the biopharmaceutical company’s stock worth $377,000 after purchasing an additional 8,282 shares in the last quarter. Institutional investors and hedge funds own 48.42% of the company’s stock.
Shares of Stemline Therapeutics, Inc. (NASDAQ STML) traded up 2.239% during trading on Friday, hitting $10.275. 150,050 shares of the stock were exchanged. The company’s market cap is $241.00 million. The firm’s 50-day moving average is $8.72 and its 200 day moving average is $8.67. Stemline Therapeutics, Inc. has a 1-year low of $5.50 and a 1-year high of $14.60.
Stemline Therapeutics (NASDAQ:STML) last posted its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.18). The company had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.30 million. Stemline Therapeutics had a negative return on equity of 67.35% and a negative net margin of 4,176.84%. Equities analysts forecast that Stemline Therapeutics, Inc. will post ($2.56) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was published by BBNS and is owned by of BBNS. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://baseballnewssource.com/markets/dimensional-fund-advisors-lp-sells-10820-shares-of-stemline-therapeutics-inc-stml/1603860.html.
A number of analysts recently commented on STML shares. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of Stemline Therapeutics in a report on Tuesday. BidaskClub upgraded shares of Stemline Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 price objective on shares of Stemline Therapeutics in a research report on Thursday, May 25th. Cowen and Company reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Wednesday, June 14th. Finally, ValuEngine downgraded shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Two investment analysts have rated the stock with a sell rating and seven have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $29.17.
Stemline Therapeutics Profile
Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.
Receive News & Ratings for Stemline Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics Inc. and related companies with our FREE daily email newsletter.